Animal Model Market to Reach USD 3.6 Billion by 2035 Amid Advances in Genetically Engineered Models

The global animal model market is witnessing dynamic growth as pharmaceutical research, biotechnology innovation, and preclinical testing requirements expand across the world. Valued at USD 2.0 billion in 2025, the market is projected to reach USD 3.6 billion by 2035, registering a compound annual growth rate (CAGR) of 6.0%. This steady growth represents an absolute dollar opportunity of USD 1.6 billion, reflecting a 1.8-times market expansion over the forecast period.

The evolution of the animal model market is closely linked to technological innovations in genetic engineering, CRISPR gene editing, and transgenic model development. Companies such as Charles River Laboratories, The Jackson Laboratory, Taconic Biosciences, Genoway SA, Eurofins Scientific, and Crown Bioscience are expanding their capabilities through investments in advanced breeding facilities, strategic partnerships, and next-generation research solutions.

Full Market Report available for delivery. For purchase or customization, please request here: https://www.futuremarketinsights.com/reports/sample/rep-gb-3141

Market Growth Drivers

Rising Pharmaceutical R&D and Personalized Medicine

Increasing pharmaceutical development investments and a rising focus on personalized medicine are significant drivers of animal model demand. Advanced disease models allow researchers to explore oncology, immunology, and rare disease therapies with higher precision and reproducibility. Animal models also play a crucial role in preclinical safety and efficacy testing, ensuring compliance with regulatory frameworks while supporting accelerated drug development timelines.

Technological Innovation in Genetic Engineering

The adoption of CRISPR-Cas9, humanized models, and transgenic mice (GEMs) has transformed the animal model market. Genetically engineered models enhance disease modeling accuracy, reduce experimental variability, and increase translational research potential, making them indispensable in modern drug discovery.

Market Expansion in Emerging Regions

Emerging markets in Asia-Pacific, Latin America, and parts of Europe are witnessing increased adoption of animal models due to growing pharmaceutical sectors, expanding research infrastructure, and government-backed biotechnology initiatives. These regions provide new opportunities for both global and regional manufacturers to expand their footprint.

Segmental Insights

Species: Mice Dominate with 65% Market Share

Mice remain the most widely used species, accounting for 65% of the market share by 2025. Their genetic similarity to humans, rapid reproductive cycles, and compatibility with disease modeling make them ideal for diverse research applications. Manufacturers are investing in advanced mouse strains, enhanced breeding technologies, and genetically engineered models to maintain market leadership and meet the rising demand for precision research tools.

Application: Drug Discovery and Development Leads

Drug discovery and development represents 55% of the market share, highlighting its critical role in pharmaceutical and biotechnology research. Genetically engineered models support targeted therapy development, personalized medicine research, and translational studies, positioning drug discovery as the primary application segment driving market growth.

End Users: CROs, Pharma, and Academic Institutions

The animal model market serves pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic and research institutions. CROs increasingly rely on specialized animal models for outsourced preclinical studies, while pharmaceutical companies focus on in-house capabilities for accelerated drug development. Academic institutions utilize models for basic research, fostering innovation in disease biology and translational science.

Regional Insights

North America Leads the Market

The USA dominates with a projected CAGR of 7.5% from 2025 to 2035, driven by robust pharmaceutical R&D infrastructure, NIH funding, and a well-established biotechnology sector. Major research hubs such as Boston, San Francisco, and the Research Triangle Park contribute to innovation and high adoption of genetically engineered models.

Emerging Growth in Brazil and Asia-Pacific

Brazil's animal model market is expected to grow at a 7.0% CAGR, fueled by pharmaceutical manufacturing expansion, academic research initiatives, and government biotechnology support. China's market aligns with the global average CAGR of 6.0%, driven by investments in domestic breeding capabilities and international partnerships. Japan demonstrates 6.5% CAGR, supported by aging population research and precision medicine developments.

European Market Expansion

Germany and France are experiencing steady growth at CAGRs of 6.4% and 6.3%, respectively, thanks to advanced pharmaceutical infrastructure, regulatory compliance, and research excellence. The UK shows a 5.9% CAGR, with growth supported by established research facilities and regulatory frameworks.

Key Market Players and Competitive Landscape

The animal model market is moderately concentrated, with both global leaders and specialized regional players driving innovation.

- Charles River Laboratories International Inc. leads with a 25% market share, leveraging global breeding facilities, comprehensive service portfolios, and partnerships with major pharmaceutical companies.
- The Jackson Laboratory specializes in genetically engineered mice and advanced transgenic models for preclinical research.
- Taconic Biosciences offers custom models, genome-editing services, and breeding solutions to meet diverse pharmaceutical and academic needs.
- Genoway SA and Eurofins Scientific SE focus on advanced disease-specific and humanized models for precision medicine applications.
- Crown Bioscience Inc. provides patient-derived xenograft (PDX) models, organ-specific disease models, and integrated preclinical platforms.

Emerging manufacturers are targeting niche applications, offering cost-effective breeding programs, regionally focused models, and specialized disease models to complement the offerings of global players. Strategic collaborations with pharmaceutical firms and academic institutions are accelerating innovation and global market penetration.

Request Market Research Draft Report: https://www.futuremarketinsights.com/reports/animal-model-market

Market Trends and Innovations

Genetically Engineered and Humanized Models

Genetic engineering applications, including CRISPR and transgenic technologies, are enabling high-precision disease modeling. Models equipped with human genes are improving translational accuracy, reducing research timelines by up to 30%, and supporting personalized medicine initiatives.

Transgenic and Patient-Derived Xenografts

Patient-derived xenografts (PDX) and organ-specific disease models are gaining traction, expanding the role of animal models beyond basic research to comprehensive drug development platforms. These specialized models enable preclinical testing of targeted therapies, oncology drugs, and rare disease treatments.

Smart Breeding and Genetic Authentication

Manufacturers are integrating genetic authentication systems to ensure model reliability and research reproducibility. Advanced breeding technologies reduce variability, maintain genetic integrity, and support large-scale preclinical studies across multiple research domains.

Challenges and Restraints

Despite growth prospects, the market faces several challenges:

- High Costs: Genetically engineered models can cost 60-80% more than conventional models, limiting adoption in cost-sensitive settings.
- Ethical and Regulatory Compliance: Animal welfare regulations require facility upgrades and trained personnel, extending research timelines and increasing operational costs by 35-45%.
- Specialized Handling Requirements: Advanced genetic models demand technical expertise and dedicated breeding infrastructure, creating barriers to entry for smaller institutions and emerging markets.

Related Reports:

DNA Polymerase Market: https://www.futuremarketinsights.com/reports/dna-polymerase-market

Hips & Knees Reconstructive Market: https://www.futuremarketinsights.com/reports/hips-and-knees-reconstructive-market

Non-Surgical Fat Reduction Market: https://www.futuremarketinsights.com/reports/non-surgical-fat-reduction-market

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

This release was published on openPR.